Cyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposide.
Patients with refractory metastatic renal cell carcinoma (RCC) were enrolled in a phase II study with teniposide (VM26) and cyclosporin A (CSA) to investigate (1) the effect of CSA on the response rate to VM26; and (2) the effect of CSA on the pharmacokinetics and pharmacodynamics of VM26. Sixteen p...
| Main Authors: | , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Nature Publishing Group|1
1997
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063346/ |